^
Association details:
| Biomarker: | BCR-ABL1 mutation |
|---|---|
| Cancer: | Acute Lymphocytic Leukemia |
| Drug: | Nailike (olverembatinib) (Bcr-abl tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Olverembatinib Based Therapy in Recurrent Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with BCR/ABL Mutation
Published date:
11/03/2022
Excerpt:
At the last follow-up, all patients responded to olverembatinib based treatment with three complete molecular remission (CMR), one complete remission (CR) and one partial remission (PR). Our results suggest that olverembatinib is effective with R/R Ph+ ALL with BCR/ABL kinase mutations and warrants broader clinical evaluation.
DOI:
10.1182/blood-2022-157416
